BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Grange DK, Hillman RE, Burton BK, Yano S, Vockley J, Fong CT, Hunt J, Mahoney JJ, Cohen-Pfeffer JL; Phenylketonuria Demographics Outcomes and Safety (PKUDOS) registry., Maternal Phenylketonuria Observational Program (PKU MOMS) sub-registry. Sapropterin dihydrochloride use in pregnant women with phenylketonuria: an interim report of the PKU MOMS sub-registry. Mol Genet Metab 2014;112:9-16. [PMID: 24667082 DOI: 10.1016/j.ymgme.2014.02.016] [Cited by in Crossref: 28] [Cited by in F6Publishing: 20] [Article Influence: 3.5] [Reference Citation Analysis]
Number Citing Articles
1 Elhawary NA, AlJahdali IA, Abumansour IS, Elhawary EN, Gaboon N, Dandini M, Madkhali A, Alosaimi W, Alzahrani A, Aljohani F, Melibary EM, Kensara OA. Genetic etiology and clinical challenges of phenylketonuria. Hum Genomics 2022;16:22. [PMID: 35854334 DOI: 10.1186/s40246-022-00398-9] [Reference Citation Analysis]
2 Altman G, Hussain K, Green D, Strauss BJG, Wilcox G. Mental health diagnoses in adults with phenylketonuria: a retrospective systematic audit in a large UK single centre. Orphanet J Rare Dis 2021;16:520. [PMID: 34930395 DOI: 10.1186/s13023-021-02138-z] [Reference Citation Analysis]
3 Boyer M, Skaar J, Sowa M, Tureson JR, Chapel-Crespo CC, Chang R. Continuation of pegvaliase treatment during pregnancy: A case report. Mol Genet Metab Rep 2021;26:100713. [PMID: 33552907 DOI: 10.1016/j.ymgmr.2021.100713] [Reference Citation Analysis]
4 Shintaku H, Ohura T, Takayanagi M, Kure S, Owada M, Matsubara Y, Yoshino M, Okano Y, Ito T, Okuyama T, Nakamura K, Matuo M, Endo F, Ida H. Guide for diagnosis and treatment of hyperphenylalaninemia. Pediatr Int 2021;63:8-12. [PMID: 33423362 DOI: 10.1111/ped.14399] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Manta-Vogli PD, Schulpis KH, Dotsikas Y, Loukas YL. Nutrition and medical support during pregnancy and lactation in women with inborn errors of intermediary metabolism disorders (IEMDs). J Pediatr Endocrinol Metab 2020;33:5-20. [PMID: 31804959 DOI: 10.1515/jpem-2019-0048] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
6 Lichter-Konecki U, Vockley J. Phenylketonuria: Current Treatments and Future Developments. Drugs 2019;79:495-500. [PMID: 30864096 DOI: 10.1007/s40265-019-01079-z] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
7 Romanowicz J, Leonetti C, Dhari Z, Korotcova L, Ramachandra SD, Saric N, Morton PD, Bansal S, Cheema A, Gallo V, Jonas RA, Ishibashi N. Treatment With Tetrahydrobiopterin Improves White Matter Maturation in a Mouse Model for Prenatal Hypoxia in Congenital Heart Disease. J Am Heart Assoc 2019;8:e012711. [PMID: 31331224 DOI: 10.1161/JAHA.119.012711] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
8 Muntau AC, Adams DJ, Bélanger-Quintana A, Bushueva TV, Cerone R, Chien YH, Chiesa A, Coşkun T, de Las Heras J, Feillet F, Katz R, Lagler F, Piazzon F, Rohr F, van Spronsen FJ, Vargas P, Wilcox G, Bhattacharya K. International best practice for the evaluation of responsiveness to sapropterin dihydrochloride in patients with phenylketonuria. Mol Genet Metab 2019;127:1-11. [PMID: 31103398 DOI: 10.1016/j.ymgme.2019.04.004] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 4.7] [Reference Citation Analysis]
9 Wilcox G. Impact of pregnancy on inborn errors of metabolism. Rev Endocr Metab Disord 2018;19:13-33. [PMID: 30198059 DOI: 10.1007/s11154-018-9455-2] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 5.0] [Reference Citation Analysis]
10 Sakamoto O, Arai-Ichinoi N, Murayama K, Kure S. Successful control of maternal phenylketonuria by tetrahydrobiopterin. Pediatr Int 2018;60:985-6. [PMID: 30345699 DOI: 10.1111/ped.13678] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
11 Kure S, Shintaku H. Tetrahydrobipterin-responsive phenylalanine hydroxylase deficiency. J Hum Genet 2019;64:67-71. [PMID: 30504912 DOI: 10.1038/s10038-018-0529-5] [Reference Citation Analysis]
12 Manta-vogli PD, Dotsikas Y, Loukas YL, Schulpis KH. The phenylketonuria patient: A recent dietetic therapeutic approach. Nutritional Neuroscience 2020;23:628-39. [DOI: 10.1080/1028415x.2018.1538196] [Cited by in Crossref: 7] [Cited by in F6Publishing: 1] [Article Influence: 1.8] [Reference Citation Analysis]
13 Kuseyri O, Weissbach A, Bruggemann N, Klein C, Giżewska M, Karall D, Scholl-Bürgi S, Romanowska H, Krzywińska-Zdeb E, Monavari AA, Knerr I, Yapıcı Z, Leuzzi V, Opladen T. Pregnancy management and outcome in patients with four different tetrahydrobiopterin disorders. J Inherit Metab Dis 2018;41:849-63. [PMID: 29594647 DOI: 10.1007/s10545-018-0169-0] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
14 van Wegberg AMJ, MacDonald A, Ahring K, Bélanger-Quintana A, Blau N, Bosch AM, Burlina A, Campistol J, Feillet F, Giżewska M, Huijbregts SC, Kearney S, Leuzzi V, Maillot F, Muntau AC, van Rijn M, Trefz F, Walter JH, van Spronsen FJ. The complete European guidelines on phenylketonuria: diagnosis and treatment. Orphanet J Rare Dis 2017;12:162. [PMID: 29025426 DOI: 10.1186/s13023-017-0685-2] [Cited by in Crossref: 206] [Cited by in F6Publishing: 167] [Article Influence: 41.2] [Reference Citation Analysis]
15 Zhu T, Ye J, Han L, Qiu W, Zhang H, Liang L, Gu X. The Predictive Value of Genetic Analyses in the Diagnosis of Tetrahydrobiopterin (BH4)-Responsiveness in Chinese Phenylalanine Hydroxylase Deficiency Patients. Sci Rep 2017;7:6762. [PMID: 28754886 DOI: 10.1038/s41598-017-06462-y] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
16 Spécola N, Chiesa A. Alternative Therapies for PKU. Journal of Inborn Errors of Metabolism and Screening 2017;5:232640981668573. [DOI: 10.1177/2326409816685734] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
17 Yildiz Y, Dursun A, Tokatli A, Coskun T, Sivri S. Partial hydatidiform mole in a phenylketonuria patient treated with sapropterin dihydrochloride. Gynecol Endocrinol 2017;33:19-20. [PMID: 27898272 DOI: 10.1080/09513590.2016.1247796] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
18 Hozyasz KK, Mostowska A, Wójcicki P, Lasota A, Zadurska M, Dunin-Wilczyńska I, Jagodziński PP. Nucleotide Variants of the BH4 Biosynthesis Pathway Gene GCH1 and the Risk of Orofacial Clefts. Mol Neurobiol 2016;53:769-76. [PMID: 26215833 DOI: 10.1007/s12035-015-9342-8] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
19 Boyer SW, Barclay LJ, Burrage LC. Inherited Metabolic Disorders: Aspects of Chronic Nutrition Management. Nutr Clin Pract 2015;30:502-10. [PMID: 26079521 DOI: 10.1177/0884533615586201] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 2.7] [Reference Citation Analysis]
20 . Committee Opinion No: 636 Management of Women With Phenylketonuria. Obstetrics & Gynecology 2015;125:1548-50. [DOI: 10.1097/01.aog.0000466372.63522.f0] [Cited by in Crossref: 2] [Article Influence: 0.3] [Reference Citation Analysis]
21 Longo N, Arnold GL, Pridjian G, Enns GM, Ficicioglu C, Parker S, Cohen-pfeffer JL. Long-term safety and efficacy of sapropterin: The PKUDOS registry experience. Molecular Genetics and Metabolism 2015;114:557-63. [DOI: 10.1016/j.ymgme.2015.02.003] [Cited by in Crossref: 29] [Cited by in F6Publishing: 23] [Article Influence: 4.1] [Reference Citation Analysis]
22 Blau N, Longo N. Alternative therapies to address the unmet medical needs of patients with phenylketonuria. Expert Opinion on Pharmacotherapy 2015;16:791-800. [DOI: 10.1517/14656566.2015.1013030] [Cited by in Crossref: 30] [Cited by in F6Publishing: 22] [Article Influence: 4.3] [Reference Citation Analysis]